ライフサイエンスコーパス: epithelial ovarian cancer

1 ar cell (rs11651755 OR=0.77, P=1.6 x 10(-8)) epithelial ovarian cancer.

2 aluation, and improved imaging strategies in epithelial ovarian cancer.

3 ic efficacy of paclitaxel in mouse models of epithelial ovarian cancer.

4 s in tumor-bearing mice and in patients with epithelial ovarian cancer.

5 o follow women during or after treatment for epithelial ovarian cancer.

6 by about 4 months in patients with advanced epithelial ovarian cancer.

7 r of angiogenesis and disease progression in epithelial ovarian cancer.

8 an initial stage in a screening strategy for epithelial ovarian cancer.

9 n and has single-agent activity in recurrent epithelial ovarian cancer.

10 ermine the potential role of CD133+ cells in epithelial ovarian cancer.

11 tatic pancreatic adenocarcinoma and advanced epithelial ovarian cancer.

12 er new biomarkers and therapeutic targets in epithelial ovarian cancer.

13 al regulatory protein often downregulated in epithelial ovarian cancer.

14 ukemia, contribute to the pathophysiology of epithelial ovarian cancer.

15 genesis can be effective in the treatment of epithelial ovarian cancer.

16 N2B, CDKN2C, and CDKN2D-and risk of invasive epithelial ovarian cancer.

17 reatment for optimally cytoreduced, advanced epithelial ovarian cancer.

18 significantly facilitate early detection of epithelial ovarian cancer.

19 in IFA) in patients with NY-ESO-1-expressing epithelial ovarian cancer.

20 in epigenetic inactivation of OPCML in human epithelial ovarian cancer.

21 s and cancer testis antigens in 117 cases of epithelial ovarian cancer.

22 loss and CpG island promoter methylation in epithelial ovarian cancer.

23 found to correlate with improved survival in epithelial ovarian cancer.

24 o are associated with favorable prognosis in epithelial ovarian cancer.

25 sing strategy for targeting ALDH activity in epithelial ovarian cancer.

26 ine option for patients with newly diagnosed epithelial ovarian cancer.

27 sk factor for and a protective agent against epithelial ovarian cancer.

28 ations in p53 are a common event in advanced epithelial ovarian cancer.

29 latin and cyclophosphamide in advanced-stage epithelial ovarian cancer.

30 metastasis in an established mouse model for epithelial ovarian cancer.

31 s is a validated clinical target in advanced epithelial ovarian cancer.

32 7S, and p.L517P), not reported previously in epithelial ovarian cancer.

33 val in a preclinical model of advanced stage epithelial ovarian cancer.

34 enesis is a valid target in the treatment of epithelial ovarian cancer.

35 oth the ovarian surface epithelium (OSE) and epithelial ovarian cancers.

36 17q21.3-q22 region that is amplified in some epithelial ovarian cancers.

37 80-2002), the authors confirmed 481 incident epithelial ovarian cancers.

38 ically amplified and overexpressed in serous epithelial ovarian cancers.

39 ecreased progression-free survival in serous epithelial ovarian cancers.

40 2 benign ovarian samples, and in 79 invasive epithelial ovarian cancers.

41 (FR), which is expressed on the majority of epithelial ovarian cancers.

42 Among 709 incident cases of epithelial ovarian cancer, 402 were serous, 74 were muci

43 were analyzed on 153 patients with invasive epithelial ovarian cancer, 42 with other ovarian cancers

44 Data were collected on 232 women with epithelial ovarian cancer, 47% of whom were receiving tr

45 Here we explore the role of LARP1 in epithelial ovarian cancer, a disease characterized by th

46 Benth suppressed the proliferation of human epithelial ovarian cancer, A2780 and the related paclita

47 the association between PID and the risk of epithelial ovarian cancer according to tumor behavior an

48 improve survival for patients with stage III epithelial ovarian cancer after a negative SLL.

49 otherwise healthy women with advanced-stage epithelial ovarian cancer aged 70 years or younger.

50 urgical diagnosis, included 42 patients with epithelial ovarian cancer and 23 patients with benign ma

51 1880 control women, 1135 women with invasive epithelial ovarian cancer and 321 women with borderline

52 thway among 829 Caucasian cases with primary epithelial ovarian cancer and 941 frequency-matched unaf

53 rapy fails in more than 20% of patients with epithelial ovarian cancer and about 40-50% of women who

54 expressed between vascular cells from human epithelial ovarian cancer and healthy ovaries.

55 stant disease after primary therapy typifies epithelial ovarian cancer and may be attributable to res

56 ave been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer

57 of tumor samples from 395 women with primary epithelial ovarian cancer and tested whether PEA-15 expr

58 purified endothelial cells from 10 invasive epithelial ovarian cancers and 5 normal ovaries using Af

59 Here, we examined the clinical (n = 93 epithelial ovarian cancers) and biological (in vitro adh

60 F) receptor (EGFR) is frequently elevated in epithelial ovarian cancer, and E-cadherin expression is

61 let-7a-3 methylation was detected in epithelial ovarian cancer, and the expression of let-7a

62 HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic si

63 gold nanoelectrode ensemble (GNEE) to detect epithelial ovarian cancer antigen-125 (CA 125), a protei

64 menopausal women who had been diagnosed with epithelial ovarian cancer (any International Federation

65 Our data suggest that histologic types of epithelial ovarian cancer are etiologically distinct.

66 Advanced-stage epithelial ovarian cancers are amongst the most difficul

67 n IGF2 were associated with risk of invasive epithelial ovarian cancer at P<0.05 and followed-up one

68 at CD11b(+)Gr-1(+) cells found in ascites of epithelial ovarian cancer-bearing mice at advanced stage

69 in fee-for-service Medicare, diagnosed with epithelial ovarian cancer between 1997 and 2007, and die

70 men aged 35-74 years who were diagnosed with epithelial ovarian cancer between 2002 and 2005 and 1,31

71 still treated by doctors who usually manage epithelial ovarian cancer but rarely see these patients.

72 We studied miRNA deregulation in human epithelial ovarian cancer by integrative genomic approac

73 Metastasis from epithelial ovarian cancer can occur via the transcoelomi

74 n a large panel of inflammatory genes in 930 epithelial ovarian cancer cases and 1,037 controls using

75 Data collected from 739 epithelial ovarian cancer cases and 1,313 community cont

76 administered to 558 histologically confirmed epithelial ovarian cancer cases and 607 population contr

77 administered to 558 histologically confirmed epithelial ovarian cancer cases and 607 population contr

78 ed case-control study comparing 608 incident epithelial ovarian cancer cases with 926 community contr

79 V) against an invasive variant of the murine epithelial ovarian cancer cell line ID8-T.

80 tumor cells, we introduced EGFRvIII into the epithelial ovarian cancer cell line OVCA 433.

81 ound that it was highly expressed in Hey, an epithelial ovarian cancer cell line.

82 effects of epigenetic treatments on a human epithelial ovarian cancer cell line.

83 or somatic H1 variants, H1.3, in the OVCAR-3 epithelial ovarian cancer cell line.

84 isolate ALDH1-bright (ALDH1(br)) cells from epithelial ovarian cancer cell lines and characterized t

85 tumour site of origin and histopathology of epithelial ovarian cancer cell lines.

86 asts from normal ovary and tumor samples and epithelial ovarian cancer cell lines.

87 eceptor and CD46 were able to trigger EMT in epithelial ovarian cancer cells and cause efficient onco

88 Metastatic epithelial ovarian cancer cells are disseminated intrape

89 of the colony-stimulating factor-1(CSF-1) by epithelial ovarian cancer cells enhances invasiveness an

90 Epithelial ovarian cancer cells express the chemokine re

91 r peptide (MV-hCEA), is potent against human epithelial ovarian cancer cells in vitro and in vivo.

92 port, we show that CXCR4 expression on human epithelial ovarian cancer cells is associated with, and

93 y, we have demonstrated that ascites-derived epithelial ovarian cancer cells lack membranal FasL but

94 In the current study, culture of epithelial ovarian cancer cells on three-dimensional col

95 ceptional antiproliferative behavior against epithelial ovarian cancer cells resistant to cisplatin.

96 ur results indicate that OvCa429 and SKOV3ip epithelial ovarian cancer cells undergo similar morpholo

97 xerted an anti-proliferative effect on human epithelial ovarian cancer cells, A2780/WT and A2780/PTX(

98 using stable knockdown and overexpression in epithelial ovarian cancer cells, we show that TG2 induce

99 iting Substance (MIS) inhibits the growth of epithelial ovarian cancer cells, which are known to be o

100 e mechanism of action of compound 1 in A2780 epithelial ovarian cancer cells.

101 ctively increased in stage III and IV serous epithelial ovarian cancers compared to other genes withi

102 hemotherapy in women with optimally debulked epithelial ovarian cancer confined to the abdominal cavi

103 The standard initial management of epithelial ovarian cancer consists of surgical staging,

104 ullerian duct adenocarcinomas, in particular epithelial ovarian cancers, continue to represent a majo

105 Based on these findings, we assert that epithelial ovarian cancers derive from a subpopulation o

106 Epithelial ovarian cancer derived from the human ovarian

107 re setting of patients with primary invasive epithelial ovarian cancers diagnosed from January 2000 t

108 associate with risk of serous and clear cell epithelial ovarian cancer; DNA methylation and expressio

109 Despite clinical remission of epithelial ovarian cancer (EOC) after surgical resection

110 Effective targets to treat advanced epithelial ovarian cancer (EOC) and biomarkers to predic

111 ncer-testis" antigen frequently expressed in epithelial ovarian cancer (EOC) and is among the most im

112 -1 is a "cancer-testis" antigen expressed in epithelial ovarian cancer (EOC) and is among the most im

113 protein (PTB) and SRp20, were upregulated in epithelial ovarian cancer (EOC) and knockdown of PTB exp

114 m published studies of Myc family targets in epithelial ovarian cancer (EOC) and neuroblastoma.

115 ms to be a promoter of tumor progression for epithelial ovarian cancer (EOC) and primary peritoneal c

116 transglutaminase 2 (TG2) is overexpressed in epithelial ovarian cancer (EOC) and promotes intraperito

117 The underlying causes of epithelial ovarian cancer (EOC) are unclear, and treatme

118 Biomarkers for early detection of epithelial ovarian cancer (EOC) are urgently needed.

119 Most women are diagnosed with epithelial ovarian cancer (EOC) at advanced stage, where

120 Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germli

121 ecule (ALCAM) is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in

122 is study, we report that a sub-population of epithelial ovarian cancer (EOC) cells co-expresses Lin28

123 ly reported that TG2 mRNA is up-regulated in epithelial ovarian cancer (EOC) cells compared with norm

124 During tumor progression, epithelial ovarian cancer (EOC) cells undergo epithelial

125 ophosphatidic acid (LPA) levels around human epithelial ovarian cancer (EOC) cells.

126 recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1, BRCA2

127 Studies of the role of dietary factors in epithelial ovarian cancer (EOC) development have been li

128 itor (PARPi) sensitivity commonly coexist in epithelial ovarian cancer (EOC) due to the high prevalen

129 Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking ang

130 Epithelial ovarian cancer (EOC) has a heritable componen

131 role of adjuvant chemotherapy in early-stage epithelial ovarian cancer (EOC) has been controversial.

132 Epithelial ovarian cancer (EOC) has poor prognosis and r

133 d validate drug-repositioning candidates for epithelial ovarian cancer (EOC) have not been undertaken

134 RAD51B, RAD51C, and RAD51D genes to invasive epithelial ovarian cancer (EOC) in the population and in

135 BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population.

136 impact of the Trp53(R172H)-mutant allele on epithelial ovarian cancer (EOC) in vivo We used the Pten

137 Epithelial ovarian cancer (EOC) is characterized by an i

138 The high mortality of epithelial ovarian cancer (EOC) is mainly caused by resi

139 Epithelial ovarian cancer (EOC) is one of the most commo

140 Epithelial ovarian cancer (EOC) is the fifth leading cau

141 Epithelial ovarian cancer (EOC) is the fifth most common

142 Epithelial ovarian cancer (EOC) is the fourth leading ca

143 Epithelial ovarian cancer (EOC) is the leading cause of

144 Epithelial ovarian cancer (EOC) is the leading cause of

145 Epithelial ovarian cancer (EOC) is the most deadly gynae

146 Epithelial ovarian cancer (EOC) is the most fatal gynaec

147 Epithelial ovarian cancer (EOC) is the most lethal gynae

148 Invasive epithelial ovarian cancer (EOC) is the most lethal gynec

149 Epithelial ovarian cancer (EOC) is the most lethal gynec

150 germ-line BRCA1/2 mutations in patients with epithelial ovarian cancer (EOC) on responses to first an

151 All patients diagnosed in Scotland with epithelial ovarian cancer (EOC) or primary peritoneal ca

152 Serous epithelial ovarian cancer (EOC) patients often succumb t

153 NY-ESO-1 (rF-NY-ESO-1) in 25 melanoma and 22 epithelial ovarian cancer (EOC) patients with advanced d

154 During epithelial ovarian cancer (EOC) progression, intraperito

155 Ascites in epithelial ovarian cancer (EOC) promotes tumor developme

156 ise genetic and molecular defects underlying epithelial ovarian cancer (EOC) remain largely unknown,

157 PURPOSE OF REVIEW: Management of the epithelial ovarian cancer (EOC) remains a therapeutic ch

158 Epithelial ovarian cancer (EOC) remains the most lethal

159 Epithelial ovarian cancer (EOC) remains the most lethal

160 g arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk.

161 cancer tissue microarrays and 56 additional epithelial ovarian cancer (EOC) samples.

162 Recently, we reported the isolation of the epithelial ovarian cancer (EOC) stem cells (type I/CD44+

163 ssociation studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles.

164 a common complication in the late stages of epithelial ovarian cancer (EOC) that greatly diminishes

165 in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin a

166 alyzed from all women in whom a diagnosis of epithelial ovarian cancer (EOC) was confirmed and from b

167 inverse association between hysterectomy and epithelial ovarian cancer (EOC) was considered well esta

168 The majority of women diagnosed with epithelial ovarian cancer (EOC) will be diagnosed with a

169 nt advances in the molecular pathogenesis of epithelial ovarian cancer (EOC) with new insights into t

170 Early diagnosis of epithelial ovarian cancer (EOC) would significantly decr

171 rous ovarian cancer is an aggressive form of epithelial ovarian cancer (EOC), and accounts for the ma

172 variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cau

173 ne protease HtrA1 as a downregulated gene in epithelial ovarian cancer (EOC), but the functional cons

174 to correlate with prognosis in patients with epithelial ovarian cancer (EOC), but their prognostic im

175 idence of breast cancer after a diagnosis of epithelial ovarian cancer (EOC), one of the tubal/perito

176 sociated with clinical outcome in women with epithelial ovarian cancer (EOC), participants that had p

177 Epithelial ovarian cancer (EOC), the leading cause of de

178 and LAGE-1 CT antigens for immunotherapy in epithelial ovarian cancer (EOC), we examined the express

179 eles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from mul

180 ox-1 is highly expressed in a mouse model of epithelial ovarian cancer (EOC), which lacks p53 but ove

181 have identified four susceptibility loci for epithelial ovarian cancer (EOC), with another two sugges

182 of coffee and tea consumption on the risk of epithelial ovarian cancer (EOC).

183 phospholipase A(2) (iPLA(2)) is involved in epithelial ovarian cancer (EOC).

184 inical impediment to effective management of epithelial ovarian cancer (EOC).

185 py develops in the majority of patients with epithelial ovarian cancer (EOC).

186 ibutes to the development and progression of epithelial ovarian cancer (EOC).

187 prognosis in several solid tumors, including epithelial ovarian cancer (EOC).

188 needed to treat platinum-sensitive recurrent epithelial ovarian cancer (EOC).

189 ly treated population of women with stage IV epithelial ovarian cancer (EOC).

190 cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC).

191 studies posit a role for non-coding RNAs in epithelial ovarian cancer (EOC).

192 ings at second-look surgery in patients with epithelial ovarian cancer (EOC).

193 n cancer [mEOC]) is a histologic subgroup of epithelial ovarian cancer (EOC).

194 ct assessment of prognosis for patients with epithelial ovarian cancer (EOC).

195 uvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC).

196 women to identify risk genetic variants for epithelial ovarian cancer (EOC).

197 taxel using an orthotopic xenograft model of epithelial ovarian cancer (EOC).

198 3 and Rb pathways are observed frequently in epithelial ovarian cancer (EOC).However, their roles in

199 Up to 50% of epithelial ovarian cancers (EOC) display defects in the

200 Highly aneuploid tumours are common in epithelial ovarian cancers (EOC).

201 the risk of estrogen receptor (ER)-positive epithelial ovarian cancers (EOC).

202 cale genomic studies have shown that half of epithelial ovarian cancers (EOCs) have alterations in ge

203 Although epithelial ovarian cancers (EOCs) have been thought to a

204 Epithelial ovarian cancers (EOCs) often exhibit morpholo

205 aracterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs).

206 inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum

207 C) is the most common and aggressive form of epithelial ovarian cancer, for which few targeted therap

208 of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a qua

209 v 19, 2012, we enrolled women with recurrent epithelial ovarian cancer from 32 countries.

210 nt validation to detect early stage invasive epithelial ovarian cancer from healthy controls, the sen

211 Patients with epithelial ovarian cancer, good end-organ function, meas

212 Epithelial ovarian cancer has a major heritable componen

213 The classification of epithelial ovarian cancer has been substantially revised

214 Patients with BRCA-associated epithelial ovarian cancer have improved response to plat

215 els for predicting absolute risk of invasive epithelial ovarian cancer have included a limited number

216 Patients with epithelial ovarian cancer have the best overall survival

217 regions conferring risk of high-grade serous epithelial ovarian cancer (HGSOC).

218 rscore distinct mechanisms driving different epithelial ovarian cancer histological subtypes.

219 Endometriosis is a risk factor for epithelial ovarian cancer; however, whether this risk ex

220 using a syngeneic orthotopic mouse model of epithelial ovarian cancer (ID8).

221 weekly paclitaxel in patients with recurrent epithelial ovarian cancer improved progression-free surv

222 sterone sulfate were associated with risk of epithelial ovarian cancer in a nested-case control study

223 k1, Bsm1, Cdx2) were associated with risk of epithelial ovarian cancer in a retrospective case-contro

224 factor alpha receptor 2-and risk of invasive epithelial ovarian cancer in prospectively collected sam

225 ified women diagnosed with incident invasive epithelial ovarian cancer in the San Francisco Bay Area

226 alyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression.

227 Epithelial ovarian cancer is a highly heterogeneous dise

228 Epithelial ovarian cancer is a leading cause of death in

229 Epithelial ovarian cancer is an aggressive malignancy, w

230 Although it is well known that epithelial ovarian cancer is moderately chemosensitive,

231 Epithelial ovarian cancer is the commonest cause of gyna

232 Epithelial ovarian cancer is the leading cause of death

233 Epithelial ovarian cancer is the leading cause of death

234 Epithelial ovarian cancer is the most frequent cause of

235 Epithelial ovarian cancer is the most frequent cause of

236 Epithelial ovarian cancer is the most lethal gynecologic

237 Epithelial ovarian cancer is the most lethal gynecologic

238 rent dietary flavonoid subclasses on risk of epithelial ovarian cancer is unclear, with limited previ

239 d we observed epigenetic silencing in serous epithelial ovarian cancer, leading us to hypothesize tha

240 uggest that the major histologic subtypes of epithelial ovarian cancer may have different risk factor

241 ve mucinous carcinoma of the ovary (mucinous epithelial ovarian cancer [mEOC]) is a histologic subgro

242 Because of the surface epithelial origin of epithelial ovarian cancer, mucins are obvious biomolecul

243 hat for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and

244 ankyrin's contribution to the development of epithelial ovarian cancer nor its interaction with folli

245 thelium (OSE) cell functions but also affect epithelial ovarian cancer (OCa) development.

246 ile estrogens are suspected risk factors for epithelial ovarian cancer (OCa), progesterone (P4) has b

247 intron 5 A>G (rs9909104) was associated with epithelial ovarian cancer [odds ratio (OR), 1.2; 95% con

248 no association between cigarette smoking and epithelial ovarian cancer of other cell types.

249 ve revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subtypes of

250 Epithelial ovarian cancer (OvCa) is associated with high

251 A third of patients with epithelial ovarian cancer (OVCA) will not respond to sta

252 f benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).

253 of (18)F-FES PET/CT for endocrine therapy in epithelial ovarian cancer patients is warranted.

254 Tumor samples from epithelial ovarian cancer patients were evaluated for ER

255 ortisol rhythms, and facets of depression in epithelial ovarian cancer patients.

256 ne tumor ERalpha expression noninvasively in epithelial ovarian cancer patients.

257 Seventy-five percent of patients with epithelial ovarian cancer present with advanced-stage di

258 so show its effectiveness in transferring an epithelial ovarian cancer prognostic gene signature acro

259 hat drive the development and progression of epithelial ovarian cancer remain obscure.

260 Women with BRCA-associated epithelial ovarian cancer represent a unique group who c

261 oms, risk factors, and prognostic factors of epithelial ovarian cancer; review the evidence for surgi

262 in this gene differentially associates with epithelial ovarian cancer risk according to histological

263 ively map variation in HNF1B with respect to epithelial ovarian cancer risk and analyse DNA methylati

264 ulating 25(OH)D concentration in relation to epithelial ovarian cancer risk.

265 r ALDH1 on a tissue microarray containing 84 epithelial ovarian cancer samples revealed that patients

266 The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by fre

267 men with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a gynec

268 angiogenesis option for women with recurrent epithelial ovarian cancer should be investigated in othe

269 ase III trial (GOG 172) in optimal stage III epithelial ovarian cancer showed that intravenous (IV) p

270 l therapy has been used erratically to treat epithelial ovarian cancer since the mid 1960s; however,

271 uated in 139 advanced, suboptimally debulked epithelial ovarian cancer specimens from patients treate

272 trix metalloproteinase was observed in human epithelial ovarian cancer specimens.

273 We found that epithelial-ovarian cancer stem cells (EOC stem cells) ar

274 d from the ascites exhibit the properties of epithelial ovarian cancer, such as anchorage-independent

275 ich have started to define biomarkers within epithelial ovarian cancers that link with hormonal respo

276 suppressed malignant proliferation in human epithelial ovarian cancer, thus proving to be a potentia

277 RL4 components are highly expressed in human epithelial ovarian cancer tissues.

278 NA expression of let-7a in 214 patients with epithelial ovarian cancer to assess the effect of let-7a

279 ent mouse model of intraperitoneal papillary epithelial ovarian cancer to show that modulation of the

280 analyzed clinical data on 619 patients with epithelial ovarian cancer to test associations between p

281 PATIENTS AND METHODS Study: participants had epithelial ovarian cancer treated with surgery followed

282 PET/CT can reliably assess ERalpha status in epithelial ovarian cancer tumors and metastases noninvas

283 nomic hybridization of 235 high-grade serous epithelial ovarian cancers using contiguous bacterial ar

284 e CT images in patients with stage III or IV epithelial ovarian cancer was independently associated w

285 p53 mutations and overexpression in advanced epithelial ovarian cancers was examined in primary tumor

286 980 and 1996, 301 incident cases of invasive epithelial ovarian cancer were confirmed among the 80,25

287 follow-up (1976-2004), 612 cases of invasive epithelial ovarian cancer were confirmed.

288 ge of 8.0 years of follow up, 2,681 cases of epithelial ovarian cancer were detected.

289 A total of 666 confirmed cases of epithelial ovarian cancer were identified over 2,790,986

290 2933 women with invasive epithelial ovarian cancer were included: 1742 with high-

291 eight patients with histologically confirmed epithelial ovarian cancer were observed from the date of

292 y and Obstetrics (FIGO) high-risk stage I-IV epithelial ovarian cancer were randomly allocated (1:1)

293 Human samples and mouse models of epithelial ovarian cancer were used to explore the under

294 illion women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous

295 ge III (incompletely resectable) or stage IV epithelial ovarian cancer who had undergone debulking su

296 patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with dru

297 ynecology stage III (n = 172) or IV (n = 31) epithelial ovarian cancer who underwent CT before primar

298 ive CT scans from patients with stage III/IV epithelial ovarian cancer who underwent primary cytoredu

299 rimary treatment most patients with advanced epithelial ovarian cancer will relapse.

300 s been implicated as a protective factor for epithelial ovarian cancers, yet little is known about it